from - http://www.drugs.com/drug_interactions.php

Drug interaction results for the following 3 drug(s):
rasagiline (Azilect)
ropinirole (Requip)
buPROPion (Wellbutrin)
Interactions between your selected drugs

Major Drug-Drug Interaction buPROPion and rasagiline (Major Drug-Drug)
CONTRAINDICATED: According to the manufacturer, the acute toxicity of bupropion may be potentiated by coadministration of monoamine oxidase inhibitors (MAOIs). The mechanism of interaction has not been described.

MANAGEMENT: Concurrent use of bupropion with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) is considered contraindicated. At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with bupropion.

Moderate Drug-Drug Interaction buPROPion and ropinirole (Moderate Drug-Drug)
MONITOR: Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.

MANAGEMENT: During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

Other drugs that your selected drugs interact with

• There are 1073 other drugs known to interact with Azilect (rasagiline)

• There are 880 other drugs known to interact with Requip (ropinirole)

• There are 1677 other drugs known to interact with Wellbutrin (buPROPion)
Interactions between your selected drugs and food

Major Drug-Food Interaction rasagiline (Major Drug-Food)
GENERALLY AVOID: Foods that contain large amounts of tyramine may precipitate a hypertensive crisis in patients treated with monoamine oxidase inhibitors (MAOIs). The mechanism is inhibition of MAO-A, the enzyme responsible for metabolizing exogenous amines such as tyramine in the gut and preventing them from being absorbed intact. Once absorbed, tyramine is metabolized to octopamine, a substance that is believed to displace norepinephrine from storage granules. Although rasagiline is considered a selective inhibitor of MAO-B, the selectivity has not been established in humans and may not be absolute even at recommended dosages. Rare cases of hypertensive reactions associated with ingestion of tyramine-containing foods have been reported in patients taking the recommended daily dose of selegiline, another MAO-B inhibitor.

MANAGEMENT: Patients treated with rasagiline should preferably avoid consumption of products that contain large amounts of amines and protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, salamis, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, sauerkraut, yogurt, papaya products, meat tenderizers, fava bean pods, protein extracts, yeast extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. At least 14 days should elapse following discontinuation of rasagiline therapy before these foods may be consumed. Specially designed reference materials and dietary consultation are recommended so that an appropriate and safe diet can be planned. Patients should also be advised to promptly seek medical attention if they experience potential signs and symptoms of a hypertensive crisis such as severe headache, visual disturbances, difficulty thinking, stupor or coma, seizures, chest pain, unexplained nausea or vomiting, and stroke-like symptoms. The recommended dosages of rasagiline should not be exceeded, as it can increase the risk of nonselective MAO inhibition and a hypertensive crisis.